scholarly article | Q13442814 |
P50 | author | Christopher deFilippi | Q43249939 |
Udo Hoffmann | Q63022682 | ||
James Januzzi | Q63144011 | ||
Myles Wolf | Q90101213 | ||
P2093 | author name string | Thomas J Wang | |
Orlando M Gutiérrez | |||
Ammar Sarwar | |||
Erin Coglianese | |||
Gina Collerone | |||
Karen Laliberte | |||
Kelsey Smith | |||
Robert Christenson | |||
Tamara Isakova | |||
P2860 | cites work | Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals | Q22252997 |
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
How fibroblast growth factor 23 works | Q28301673 | ||
Fibroblast growth factor-2 mediates pressure-induced hypertrophic response | Q28343582 | ||
Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro | Q28565692 | ||
Prevalence of chronic kidney disease in the United States | Q29614191 | ||
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 | ||
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23 | Q34075026 | ||
Left ventricular hypertrophy in the renal patient | Q34228252 | ||
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function | Q36095572 | ||
The mechanism of phosphorus as a cardiovascular risk factor in CKD | Q36677622 | ||
Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues | Q38474392 | ||
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study | Q40403628 | ||
Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention | Q40949366 | ||
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance | Q41979332 | ||
Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects | Q43573502 | ||
Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems | Q45059018 | ||
Chronic kidney disease predicts cardiovascular disease | Q45072901 | ||
Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. | Q45197408 | ||
Serum phosphate levels and mortality risk among people with chronic kidney disease | Q45198981 | ||
Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences | Q46318788 | ||
Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. | Q46533837 | ||
Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients | Q46631801 | ||
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease | Q46772376 | ||
The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. | Q46987014 | ||
N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients | Q48552289 | ||
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients. | Q50777435 | ||
Quantification of coronary artery calcium using ultrafast computed tomography. | Q52867038 | ||
Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. | Q53455976 | ||
Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. | Q54173211 | ||
Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. | Q54269247 | ||
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 | ||
Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study | Q59575076 | ||
Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study | Q60777269 | ||
Improved electrocardiographic diagnosis of left ventricular hypertrophy | Q72759885 | ||
Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy | Q73833050 | ||
Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis | Q77309263 | ||
Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats | Q77481811 | ||
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients | Q79478108 | ||
Coronary calcification improves cardiovascular risk prediction in the elderly | Q80357431 | ||
Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy individuals and patients with compensated heart failure | Q81453785 | ||
Impact of left ventricular hypertrophy on survival in end-stage renal disease | Q93520188 | ||
P433 | issue | 19 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | left ventricular hypertrophy | Q1628627 |
P304 | page(s) | 2545-2552 | |
P577 | publication date | 2009-05-04 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease | |
P478 | volume | 119 |
Q35755817 | 1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure |
Q37552700 | A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease |
Q38140738 | A short story of Klotho and FGF23: a deuce of dark side or the savior? |
Q36348861 | Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy |
Q34683694 | Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study. |
Q47098883 | Albuminuria and kidney function as prognostic marker of left ventricular mass among South Asians with hypertension |
Q35782011 | Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation |
Q34641464 | An update on uremic toxins |
Q34663898 | Arterial klotho expression and FGF23 effects on vascular calcification and function |
Q36072709 | Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages |
Q34988878 | Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients |
Q40643620 | Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study |
Q88517168 | Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial |
Q52667905 | Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults. |
Q50912508 | Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients. |
Q40229714 | Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients |
Q40106923 | Association of pre-operative estimated GFR on post-operative pulmonary complications in laparoscopic surgeries. |
Q89260331 | Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis |
Q34204949 | Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients |
Q37126261 | Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure |
Q36044367 | Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease |
Q36227387 | Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease |
Q92157066 | Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study |
Q35875497 | Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA). |
Q42870432 | Asymptomatic Ventricular Arrhythmia and Clinical Outcomes in Chronic Kidney Disease: A Pilot Study |
Q50636871 | Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients. |
Q92153321 | Bone and heart health in chronic kidney disease: role of dentin matrix protein 1 |
Q34261737 | Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients |
Q64054921 | Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis |
Q33974636 | CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder |
Q38576402 | Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures |
Q46432103 | Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism |
Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
Q27687570 | Calcium and phosphate impact cardiovascular risk |
Q38941532 | Calcium as a cardiovascular toxin in CKD-MBD. |
Q26863412 | Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease |
Q92070155 | Cardiac FGF23: a new player in myocardial infarction |
Q38977291 | Cardiac actions of fibroblast growth factor 23. |
Q57452637 | Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: An Experimental and Clinical Studies |
Q35893998 | Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia |
Q58773641 | Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome |
Q46002983 | Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene. |
Q58770788 | Cardiovascular Interactions between Fibroblast Growth Factor-23 and Angiotensin II |
Q27024043 | Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease |
Q38025185 | Cardiovascular disease in chronic kidney disease: untying the Gordian knot |
Q101038925 | Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis |
Q38052430 | Cardiovascular risk assessment in children with chronic kidney disease |
Q37670438 | Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. |
Q52604286 | Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials. |
Q37483194 | Changes in Serum Concentrations of Fibroblast Growth Factor 23 and Soluble Klotho in Hemodialysis Patients after Total Parathyroidectomy. |
Q33937415 | Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial |
Q90419329 | Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats |
Q89762306 | CharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function Deterioration |
Q37053525 | Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysis |
Q89545116 | Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? |
Q38016491 | Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications |
Q34402661 | Chronic kidney disease: mineral and bone disorder in children |
Q34739121 | Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study |
Q84847501 | Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism |
Q57218945 | Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism |
Q46921995 | Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism |
Q37993874 | Cinacalcet: will it play a role in reducing cardiovascular events? |
Q28477784 | Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese |
Q54965740 | Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease. |
Q33736093 | Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active |
Q34981550 | Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease |
Q34989319 | Clinical Significance of FGF-23 in Patients with CKD. |
Q56761591 | Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients |
Q38784139 | Clinical features of CKD-MBD in Japan: cohort studies and registry |
Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
Q38096829 | Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin |
Q48951447 | Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats. |
Q35067500 | Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease |
Q90450534 | Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management |
Q64087850 | DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease |
Q39249797 | Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease |
Q52673652 | Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway. |
Q35895880 | Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials. |
Q35953344 | Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. |
Q36728820 | Dietary phosphorus is associated with greater left ventricular mass |
Q87375449 | Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease |
Q37553097 | Disordered FGF23 and mineral metabolism in children with CKD |
Q37801814 | Disorders of phosphorus homeostasis |
Q37891153 | Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? |
Q35646353 | Effect of High-Flux Dialysis on Circulating FGF-23 Levels in End-Stage Renal Disease Patients: Results from a Randomized Trial |
Q53822817 | Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method. |
Q33914268 | Effect of niacin on FGF23 concentration in chronic kidney disease |
Q41113729 | Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure |
Q36614486 | Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients |
Q46248791 | Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice |
Q34639705 | Effects of dietary phosphate and calcium intake on fibroblast growth factor-23 |
Q90209853 | Effects of erythropoietin on fibroblast growth factor 23 in mice and humans |
Q57214530 | Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients |
Q30658399 | Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease |
Q57214044 | Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients |
Q34755816 | Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease |
Q53241475 | Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. |
Q34428293 | Elevated cardiac markers in chronic kidney disease as a consequence of hyperphosphatemia-induced cardiac myocyte injury |
Q30427104 | Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality |
Q49152067 | Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure |
Q38674256 | Elevation of plasma oncostatin M in heart failure |
Q43236381 | Emerging risk factors and markers of chronic kidney disease progression |
Q53810866 | Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment. |
Q35997370 | Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. |
Q36495082 | Estimated GFR and Subsequent Higher Left Ventricular Mass in Young and Middle-Aged Adults With Normal Kidney Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study |
Q84904076 | Evaluation of a new automated chemiluminescence immunoassay for FGF23 |
Q48191834 | Evaluation of potential long-term changes in endothelial functions and basic echocardiographic parameters in unilateral nephrectomy patients |
Q91142496 | Evolving concepts in the pathogenesis of uraemic cardiomyopathy |
Q38960643 | FGF-23 and cardiovascular disease: review of literature. |
Q35647125 | FGF-23 and cognitive performance in hemodialysis patients |
Q39866881 | FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment |
Q36443208 | FGF-23 and the progression of coronary arterial calcification in patients new to dialysis |
Q42976674 | FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease |
Q34639537 | FGF-23 as a Predictor of Renal Outcome in Diabetic Nephropathy |
Q35030290 | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients |
Q35272291 | FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis |
Q37291894 | FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock |
Q52985054 | FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients. |
Q52977075 | FGF-23 levels in patients with critical carotid artery stenosis. |
Q86525641 | FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients |
Q35827508 | FGF-23, α-Klotho Gene Polymorphism and Their Relationship with the Markers of Bone Metabolism in Chronic Peritoneal Dialysis Patients |
Q35156017 | FGF-23: More than a regulator of renal phosphate handling? |
Q38031216 | FGF-23: the rise of a novel cardiovascular risk marker in CKD. |
Q88523645 | FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study |
Q53088891 | FGF23 affects the lineage fate determination of mesenchymal stem cells. |
Q46192114 | FGF23 and Left Ventricular Hypertrophy in Children with CKD. |
Q37228152 | FGF23 and mineral metabolism in the early post-renal transplantation period |
Q27687769 | FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease |
Q91697808 | FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model |
Q38728860 | FGF23 from bench to bedside. |
Q41186366 | FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde |
Q91410209 | FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice |
Q34028891 | FGF23 induces left ventricular hypertrophy |
Q34035797 | FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy |
Q53189719 | FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. |
Q36068303 | FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality |
Q37662106 | FGF23 promotes myocardial fibrosis in mice through activation of β-catenin |
Q35917428 | FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy |
Q90195274 | FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis |
Q33694566 | FGF23/FGFR4-mediated left ventricular hypertrophy is reversible |
Q38111898 | FGF23: a mature renal and cardiovascular risk factor? |
Q46004871 | Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. |
Q88284298 | Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline |
Q42234272 | Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients |
Q28075648 | Fibroblast Growth Factor-23-A Potential Uremic Toxin |
Q36067879 | Fibroblast growth factor 23 and Inflammation in CKD |
Q48461689 | Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients |
Q35965337 | Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease |
Q37280819 | Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation |
Q34281341 | Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease |
Q41091515 | Fibroblast growth factor 23 and heart failure: the plot thickens |
Q34828731 | Fibroblast growth factor 23 and incident CKD in type 2 diabetes. |
Q84403337 | Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis |
Q47817743 | Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis |
Q40268402 | Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease |
Q35019943 | Fibroblast growth factor 23 and risk of incident stroke in community-living adults |
Q34027316 | Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease |
Q51199021 | Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. |
Q35797940 | Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study |
Q37913097 | Fibroblast growth factor 23 as a phosphotropic hormone and beyond |
Q40279706 | Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis |
Q34280125 | Fibroblast growth factor 23 in acute kidney injury |
Q35008805 | Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial |
Q37832285 | Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications |
Q34557041 | Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study |
Q35099518 | Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease |
Q36901897 | Fibroblast growth factor 23 is not associated with and does not induce arterial calcification |
Q35157648 | Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation |
Q48891787 | Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density. |
Q36791903 | Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy |
Q37071263 | Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study |
Q35664606 | Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study |
Q36476324 | Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. |
Q37342971 | Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults |
Q34669005 | Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). |
Q37589683 | Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study |
Q96647282 | Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction |
Q90043642 | Fibroblast growth factor 23: are we ready to use it in clinical practice? |
Q38072361 | Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease |
Q46567248 | Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients |
Q34039877 | Fibroblast growth factor-23 and cardiac structure and function |
Q37524119 | Fibroblast growth factor-23 and cardiovascular events in CKD. |
Q36095111 | Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). |
Q33988990 | Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study |
Q33940724 | Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). |
Q35021985 | Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study |
Q87406390 | Fibroblast growth factor-23 and renin-angiotensin system levels in vitamin-D-dependent rickets type I |
Q40115641 | Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy |
Q35967107 | Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease |
Q34255342 | Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure |
Q44716347 | Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease |
Q45271516 | Fibroblast growth factor-23 levels are associated with uric acid but not carotid intima media thickness in renal transplant recipients |
Q54700038 | Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients. |
Q34421217 | Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease |
Q37162723 | Fibroblast growth factor-23: what we know, what we don't know, and what we need to know |
Q58760089 | Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes |
Q28084197 | Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21 |
Q41200048 | Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload. |
Q35138993 | Heart failure and atrial fibrillation: from basic science to clinical practice |
Q55399715 | High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes. |
Q30564821 | High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. |
Q47843993 | High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications |
Q36287699 | High-Flux Hemodialysis Benefits Hemodialysis Patients by Reducing Serum FGF-23 Levels and Reducing Vascular Calcification. |
Q33600110 | Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients |
Q95407461 | Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community |
Q43207404 | Hunt for the culprit of cardiovascular injury in kidney disease |
Q89161363 | Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature |
Q55413743 | Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23. |
Q35837789 | Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients |
Q35207828 | Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry |
Q52720297 | Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH. |
Q36156920 | Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis |
Q45339625 | Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation. |
Q52894312 | Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. |
Q48006325 | Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease |
Q41305100 | Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. |
Q41217019 | Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome |
Q39456034 | Interorgan handling of fibroblast growth factor-23 in humans. |
Q34040279 | Intersection of cardiovascular disease and kidney disease: atrial fibrillation |
Q48045737 | Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model |
Q34650666 | Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations |
Q92562108 | Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study |
Q39440902 | Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? |
Q35207839 | Iron-based phosphate binders: do they offer advantages over currently available phosphate binders? |
Q37760853 | Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications? |
Q37851395 | Is fibroblast growth factor 23 a harbinger of mortality in CKD? |
Q38258133 | Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease |
Q53342879 | Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management? |
Q55300798 | Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels. |
Q91659301 | Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial |
Q64231913 | Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern |
Q38444264 | Left Ventricular Diastolic Dysfunction in End-Stage Kidney Disease: Pathogenesis, Diagnosis, and Treatment |
Q33791650 | Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. |
Q36172106 | Long term evolution of endothelial function during kidney transplantation. |
Q58946285 | Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation |
Q40500215 | Longitudinal assessment of cardiac morphology and function following kidney transplantation |
Q36227410 | Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease |
Q36417886 | Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study |
Q37029683 | Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23. |
Q41003926 | Markers of bone remodeling are associated with arterial stiffness in renal transplanted subjects |
Q40721152 | Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study |
Q49620885 | MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4. |
Q36123640 | Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014 |
Q89996076 | Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation |
Q37938689 | Mineral and bone disorders in children with chronic kidney disease |
Q36994038 | Mineral metabolic abnormalities and mortality in dialysis patients |
Q34550213 | Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. |
Q47132894 | New Insights into the Mechanism of Action of Soluble Klotho |
Q30979522 | Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients |
Q57796697 | Non-renal-Related Mechanisms of FGF23 Pathophysiology |
Q36225208 | Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease |
Q38245327 | Novel metabolic biomarkers of cardiovascular disease |
Q49166621 | Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes |
Q55221465 | Paracrine Effects of FGF23 on the Heart. |
Q51714847 | Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease. |
Q90462704 | Parathyroid Hormone: A Uremic Toxin |
Q34989448 | Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. |
Q35069203 | Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion |
Q37690771 | Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats |
Q26853186 | Pathophysiological roles of FGF signaling in the heart |
Q49908584 | Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease |
Q37520430 | Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies |
Q34213752 | Pharmacology, efficacy and safety of oral phosphate binders |
Q54357184 | Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT). |
Q36965142 | Phosphate Toxicity in CKD: The Killer among Us |
Q55098165 | Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification. |
Q24610674 | Phosphate and FGF-23 |
Q33566596 | Phosphate and cardiovascular disease |
Q38079128 | Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children |
Q58797979 | Phosphate control in reducing FGF23 levels in hemodialysis patients |
Q38049170 | Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate |
Q38009044 | Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk |
Q38060627 | Phosphate is a vascular toxin |
Q35998095 | Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study |
Q37492019 | Phosphate: an old bone molecule but new cardiovascular risk factor |
Q36236289 | Phosphocalcic Markers and Calcification Propensity for Assessment of Interstitial Fibrosis and Vascular Lesions in Kidney Allograft Recipients |
Q42123269 | Phosphorus metabolism in chronic kidney disease |
Q35025469 | Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease |
Q36520483 | Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus |
Q33654616 | Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS) |
Q85316417 | Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD |
Q64108575 | Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension |
Q37240698 | Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study |
Q86360000 | Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study |
Q85212298 | Plasma fibroblast growth factor‐23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients |
Q30316351 | Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study |
Q28468444 | Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis |
Q33591588 | Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). |
Q85892981 | Preoperative plasma FGF23 levels predict acute kidney injury in children: results of a pilot study |
Q59335712 | Quantitative Gadolinium-Free Cardiac Fibrosis Imaging in End Stage Renal Disease Patients Reveals A Longitudinal Correlation with Structural and Functional Decline |
Q35860700 | Racial differences in markers of mineral metabolism in advanced chronic kidney disease |
Q37248630 | Recent advances in the noninvasive diagnosis of renal osteodystrophy |
Q37783496 | Reciprocal Control of 1,25-Dihydroxyvitamin D and FGF23 Formation Involving the FGF23/Klotho System |
Q26860470 | Regulation and function of the FGF23/klotho endocrine pathways |
Q35665003 | Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure |
Q43109219 | Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? |
Q34479134 | Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease |
Q45030154 | Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients |
Q87311239 | Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease |
Q53149178 | Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. |
Q100428073 | Relative overhydration is independently associated with left ventricular hypertrophy in dialysis naïve patients with stage 5 chronic kidney disease |
Q92354701 | Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study |
Q34962806 | Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor |
Q38042591 | Renalase, hypertension, and kidney - the discussion continues |
Q38141236 | Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. |
Q34634066 | Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. |
Q38164437 | Risk of sudden cardiac death in chronic kidney disease |
Q35755137 | Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models |
Q55315635 | Role of Fibroblast Growth Factor-23 in Innate Immune Responses. |
Q38200883 | Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. |
Q33939707 | S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner |
Q95411416 | Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers |
Q56109733 | Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men |
Q84976574 | Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients |
Q34254746 | Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting. |
Q90099487 | Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial |
Q26782946 | Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease |
Q38847325 | Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD. |
Q89479278 | Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos |
Q35550609 | Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate |
Q92663763 | Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis |
Q40478704 | Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation. |
Q64104905 | Sudden Cardiac Death in Dialysis: Arrhythmic Mechanisms and the Value of Non-invasive Electrophysiology |
Q34500628 | Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation |
Q64118923 | The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research |
Q35914820 | The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease |
Q93180147 | The FGF metabolic axis |
Q38644586 | The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study |
Q24625902 | The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis |
Q38571195 | The PTH-Vitamin D-FGF23 axis |
Q50101289 | The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease |
Q52146506 | The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. |
Q34022484 | The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. |
Q37296494 | The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know |
Q38545213 | The dynamic skeleton |
Q45134043 | The fibroblast growth factor-23 and Vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk |
Q38255386 | The impact of arteriovenous fistulae on the myocardium: the impact of creation and ligation in the transplant era. |
Q48122785 | The impact of calcineurin inhibitors on neutrophil gelatinase-associated lipocalin and fibroblast growth factor 23 in long-term kidney transplant patients |
Q38053246 | The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications |
Q34027561 | The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation |
Q38244314 | The role of bone in CKD-mediated mineral and vascular disease |
Q36963471 | The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy |
Q53989980 | The role of fibroblast growth factor-23 in cardiorenal syndrome. |
Q26823897 | The role of phosphorus in the development and progression of vascular calcification |
Q30234695 | The systemic nature of CKD. |
Q33835743 | The use of fibroblast growth factor 23 testing in patients with kidney disease |
Q38605457 | Therapeutic effect of CNP on renal osteodystrophy by antagonizing the FGF-23/MAPK pathway |
Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
Q35588217 | Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. |
Q64990625 | Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study. |
Q58578167 | Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease |
Q36210285 | Update on fibroblast growth factor 23 in chronic kidney disease |
Q37809763 | Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation? |
Q55496554 | Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. |
Q88172233 | Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction |
Q34037021 | Vascular calcification in chronic kidney disease: role of disordered mineral metabolism |
Q35278497 | Vascular calcification in patients with nondialysis CKD over 3 years |
Q28071582 | Vascular calcification: When should we interfere in chronic kidney disease patients and how? |
Q34385273 | Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects |
Q88648846 | Vitamin D and Calcimimetics in Cardiovascular Disease |
Q38624627 | Vitamin D and Heart Failure. |
Q38878795 | Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. |
Q37737597 | Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? |
Q86277253 | [FGF23 and the heart] |
Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.